Cargando…
Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502105/ https://www.ncbi.nlm.nih.gov/pubmed/36145301 http://dx.doi.org/10.3390/ph15091080 |
_version_ | 1784795625491005440 |
---|---|
author | Song, Yijie Yuan, Man Xu, Yu Xu, Hongxi |
author_facet | Song, Yijie Yuan, Man Xu, Yu Xu, Hongxi |
author_sort | Song, Yijie |
collection | PubMed |
description | Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over recent years and are promising options for treating IBD. Antagonizing interleukins, interferons, and Janus kinases have demonstrated their respective advantages in clinical trials and are candidates for anti-TNF therapeutic failure. Furthermore, the blockade of lymphocyte homing contributes to the excessive immune response in colitis and ameliorates inflammation and tissue damage. Factors such as integrins, selectins, and chemokines jointly coordinate the accumulation of immune cells in inflammatory regions. This review assembles the major targets and agents currently targeting proinflammatory cytokines and lymphatic trafficking to facilitate subsequent drug development. |
format | Online Article Text |
id | pubmed-9502105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95021052022-09-24 Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing Song, Yijie Yuan, Man Xu, Yu Xu, Hongxi Pharmaceuticals (Basel) Review Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over recent years and are promising options for treating IBD. Antagonizing interleukins, interferons, and Janus kinases have demonstrated their respective advantages in clinical trials and are candidates for anti-TNF therapeutic failure. Furthermore, the blockade of lymphocyte homing contributes to the excessive immune response in colitis and ameliorates inflammation and tissue damage. Factors such as integrins, selectins, and chemokines jointly coordinate the accumulation of immune cells in inflammatory regions. This review assembles the major targets and agents currently targeting proinflammatory cytokines and lymphatic trafficking to facilitate subsequent drug development. MDPI 2022-08-30 /pmc/articles/PMC9502105/ /pubmed/36145301 http://dx.doi.org/10.3390/ph15091080 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Song, Yijie Yuan, Man Xu, Yu Xu, Hongxi Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title | Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title_full | Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title_fullStr | Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title_full_unstemmed | Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title_short | Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing |
title_sort | tackling inflammatory bowel diseases: targeting proinflammatory cytokines and lymphocyte homing |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502105/ https://www.ncbi.nlm.nih.gov/pubmed/36145301 http://dx.doi.org/10.3390/ph15091080 |
work_keys_str_mv | AT songyijie tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming AT yuanman tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming AT xuyu tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming AT xuhongxi tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming |